Anna Rose Welch articles

  1. One Way Biosimilar Manufacturers Could Improve Payer Relationships
    8/7/2018

    Outside the world of rebate traps, product bundling, and seemingly water-tight innovator contracting efforts, there is certainly still room for biosimilar manufacturers to improve their own payer strategies. Ned Pojskic, an expert from Green Shield Canada, shares one simple solution.

  2. The Great Canadian Biosimilar Transition: One Payer’s Strategy
    7/31/2018

    Green Shield Canada, a private payer, has created a biosimilar policy and is currently rolling out a pilot biosimilar transition program among its clients. Though it’s still in the early stages, this is an intriguing program to keep our eyes on as the market advances in Canada.

  3. Biosimilars Conquer Factual Hurdle, Now Face “Emotional Hurdle”
    7/26/2018

    Conversations about biosimilars amongst stakeholders are beginning to shift in the way that we’d like them to. The industry no longer needs to (stringently) justify the science so much as provide information on how the product can be used. One expert shares some recent revelations she plans to turn into actionable strategies in her role at Mylan and with Medicines for EU.

  4. The Search For Biosimilar Value: The Devil Is In The Details
    7/24/2018

    In many situations, value is associated with the price tag, and, specifically, the savings associated with a certain product. But there are still questions of how biosimilar value can be presented to stakeholders, especially since it can feel as though there is a missing part in the equation.

     

  5. What To Watch In The Biosimilar Regulatory Space
    7/16/2018

    Though none of the regulatory issues discussed will be resolved right away, you can guarantee these will become regular parts of the dialogue between the industry and regulators in the years ahead.

  6. EU Turns Focus To Biosimilar Sustainability Questions
    7/11/2018

    As Julie Maréchal-Jamil of Medicines for Europe shared, the biggest questions in Europe now circle around sustainability — particularly whether market policies, procurement mechanisms, and benefit sharing models are in sync with the system's needs, and if they can teach nations that have yet to seize the biosimilar opportunity.

  7. Samsung Bioepis: Applying The "Hunger" For Biosimilars To Novel Drugs
    7/3/2018

    Since last year's feature article celebrating Samsung Bioepis' fifth anniversary, the company has seen a number of approvals and launches and has established a novel biologics development partnership. As such, I jumped on the opportunity to learn more about the company's ongoing efforts to realize a lower COGS, speed production, and manage risk in biosimilar and biologics development.

  8. Why The Biosimilar Industry Should Celebrate The Latest FDA News
    6/28/2018

    A number of articles already provide a synopsis of the FDA's reversal on the Statistical Approaches draft guidance. But I felt it was necessary to add one more article to this conversation, not only because this action is unprecedented thus far in the biosimilar industry, but it also suggests an important turning point in the FDA’s biosimilar oversight.

  9. “Locally Brilliant": 3 Biosimilar Market Access Experiences
    6/25/2018

    Mundipharma expert Richard Trollope shares his learnings from launching three different biosimilar molecules (Remsima, Truxima, and Herzuma) in the EU and discusses the questions that remain about the newly launched Herzuma, recently introduced in the U.K. and Germany.

  10. 4 Conversations Integral To Building Biosimilar Partnerships
    6/19/2018

    Thanks to Mundipharma's Richard Trollope, I not only got the inside scoop on what makes a biosimilar partnership specifically a biosimilar partnership, but also Mundipharma’s journey in launching Remsima, Truxima, and, most recently, Herzuma.